热门资讯> 正文
Clearside Biomedical自愿申请破产
2025-11-24 20:15
- Intended to Maximize Stakeholder Value Through a Structured Process.
- Validated SCS Microinjector Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential.
- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy.
- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。